GSK
-
GSK’s Bepirovirsen under EMA review for chronic hepatitis B
Chronic hepatitis B affects an estimated 3.2 million people in Europe alone and more than 250 million people globally.
-
GSK to support UK meningitis B vaccine expansion following Kent outbreak
The UK Health Security Agency (UKHSA) has launched a targeted vaccination programme, beginning with students residing at the University of Kent.
-
FDA expands GSK’s Arexvy approval to high-risk adults aged 18-49
The FDA based its approval decision on data from a global Phase IIIb clinical trial demonstrating Arexvy’s effectiveness in the younger adult population.
-
Alfasigma acquires GSK’s liver disease drug Linerixibat for USD690M deal
Alfasigma will pay GSK USD 300 million upfront, with an additional USD 100 million due upon US Food and Drug Administration (FDA) approval.
-
-
GSK renews USD250M manufacturing deal with Bora Pharmaceuticals through 2030
Under the renewed agreement, Bora will provide end-to-end manufacturing services for more than 20 commercial GSK product lines.
-
GSK invests over USD1B in Frontier Biotechnologies’ RNA-based kidney disease therapies
The pharmaceutical giant will pay Frontier USD 40 million upfront, with additional payments of up to USD 963 million tied to achieving specific development, regulatory, and commercial milestones.
-
GSK acquires Rapt Therapeutics for USD2.2B to advance long-acting food allergy treatments
The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.
-
GSK expands its respiratory portfolio with FDA-approved long-acting biologic exdensur
The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.